ASX Release
20 November 2026

ASX code: PIQ

2026 Annual General Meeting

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to present the Chair's Address and Company Presentation to be presented at the Company's Annual General Meeting today.

Chair's Address

Good morning, and welcome to the 2026 Annual General Meeting of Proteomics International. Thank you for joining us and for your continued support of the Company.

This has been a year of transition. Proteomics has moved from a predominantly research-focused company to a commercially-focused diagnostics business, with a practical route to bring our tests to clinicians and patients. David will take you through the operational detail and progress behind that shift. I will focus on the decisions the Board has taken, how we are overseeing their delivery and the Company's funding position.

The Board is confident in the direction of the business. That confidence rests on the capabilities now in place: a proprietary technology platform, three core tests addressing important clinical needs, accredited laboratories, a national distribution partnership with Healius and an aligned and focused team. Together, they give us a strong basis for building a business that serves patients and generates revenue.

The opportunity starts with a simple purpose – that better information about disease can help clinicians make more informed decisions. For shareholders, the opportunity is to build a commercial business around those clinical needs and the technology we have developed to address them.

David Morris joined as Chief Executive Officer and Managing Director in January, bringing extensive healthcare and medical technology experience. Working with the Board and the team, he led a strategic and operational review that sharpened the Company's commercial priorities and changed how it goes to market.

Following that review, we adopted a distributor-led approach, discontinued the direct-to-consumer model and restructured the organisation. These decisions have focused our people and resources on building adoption and delivering reliable testing.

The Healius agreement, signed in July, puts that strategy into practice. It combines Healius' established collection network with our tests, specialist laboratory capability and clinical reporting, giving us national access without building our own pathology collection network. Importantly, it is a pathway that can serve future products as well as current ones, so investment can follow evidence and demand rather than the cost of building a new route to market for each test.

Scientific innovation remains essential to our future. Our commercial focus gives that work a clear purpose: developing useful tests, protecting the technology behind them and building the evidence clinicians and payers need. Our immediate priority is to realise the potential of the core portfolio.

Australia is our initial commercial market. The United States offers a further opportunity, which we intend to pursue through suitable distribution partners and staged investment, assessed against market readiness, reimbursement requirements and available funding.

The Board's responsibility is to support this opportunity with sound judgement and careful use of shareholders' capital. We will assess progress against the priorities and milestones that David will outline, direct investment towards the activities most likely to advance adoption and maintain close oversight of quality and financial performance.

Funding remains important. We continue to manage expenditure and funding requirements closely.

The Share Purchase Plan announced on 2 November seeks to raise up to $5 million before costs to support the commercial plan. Eligible shareholders can apply for up to $30,000 of shares at 10 cents per share. Subject to shareholder approval, each new share will carry one free attaching option, exercisable at 15 cents and expiring two years from issue. The options will be offered under a separate prospectus, with the relevant approvals forming part of today's meeting. The SPP is scheduled to close on 25 November 2026, unless varied under its terms.

Assuming the full $5 million is raised, the funding package, including reported September cash and the R&D tax incentive is expected to support operations to October 2027 based on Company forecasts, and not factoring for any Promarker revenue. The funds are intended to support Australian adoption, the planned Endo introduction, reimbursement work, laboratory operations and US market readiness. These align with the priorities David will set out.

Before we move to the formal business, I want to acknowledge our founder, Dr Richard Lipscombe, who retired from his executive and Board roles during the year after 25 years of leadership.

Richard founded this company and built it from a small laboratory with a big idea into the diagnostics business on the cusp of commercialisation we are today. Leading a life sciences company for a quarter of a century is rare, and it takes real conviction and persistence. His contribution, together with the work of our scientists and collaborators, established the platform we are now commercialising.

On behalf of the Board and shareholders, thank you, Richard, for your vision and dedication. We wish you every success and enjoyment in retirement, and we hope you take great pride in watching the business you started grow from here.

On behalf of the Board, I also thank David and all of our staff for their commitment through a period of considerable change, and my fellow directors, past and present, for their contributions.

To our shareholders, thank you for your continued support. We recognise the commitment you have made, and we take seriously our responsibility to turn this progress into lasting value.

The Company has a strong foundation, a clear commercial strategy and important opportunities ahead. The Board's focus is on disciplined delivery and on building the value of this business for shareholders.

We will now proceed with the formalities of the AGM, after which I will ask David to provide an update.

CEO and Managing Director's Address

Introduction

Thank you, James, and good morning.

Since joining Proteomics International in January, my focus has been to turn our scientific achievements into commercial success. Promarker D and Promarker Eso are now commercially available across Australia, and Promarker Endo is progressing towards launch. Our next task is to build clinician adoption and grow revenue.

James has outlined our strategy. I will explain what we have delivered and our priorities for the next stage of growth.

Execution Plan Achievements to Date

Our execution plan began with resetting the business. We discontinued the direct-to-consumer model, restructured the leadership team and organisation, and shifted our focus to a distribution partner model. This gives us a clearer commercial focus and access to established pathology networks.

We then moved to establishing market access. We appointed Healius, launched Promarker D and Promarker Eso in Australia, and refined and independently validated Promarker Endo. We also developed our reimbursement strategy for Australia and the United States.

We have strengthened the operations supporting this work. Our Australian Diagnostics Facility added testing capacity and automation within our ISO 15189-accredited laboratory. Our Irvine laboratory achieved College of American Pathologists accreditation, complementing its existing US certification. These capabilities support quality testing as we build demand.

Product Innovation Promarker Portfolio

Every one of our tests starts with a person looking for clearer answers about their health. Our three tests each meet a distinct clinical need.

Promarker D gives people with type 2 diabetes and their clinicians information about kidney disease risk up to four years before clinical symptoms appear. It is designed to support earlier intervention and ongoing monitoring.

Promarker Eso is designed to assist in ruling out a type of oesophageal cancer in patients with chronic reflux. It supports decisions about further investigation, including endoscopy.

Promarker Endo is intended to give clinicians additional information when assessing women with suspected endometriosis and deciding what further care is appropriate. In October, we completed refinement and independent validation of the model underpinning the test, an important step towards making it available.

Our priority is to commercialise these three tests before developing tests for other medical conditions.

Distribution Healius Partnership

Promarker D and Promarker Eso are now commercially available nationally. Controlled market release began in Western Australia and the Northern Territory in September, followed by national rollout on 26 October 2026.

Healius gives us national reach through approximately 1,900 collection centres and established relationships with referring clinicians. We provide the testing, clinical reporting and scientific support. This allows us to reach patients through existing pathology infrastructure without building our own collection network.

Sales teams have completed training and joint marketing plans are in place. Laboratory workflows and systems integration support the pathway from a clinician requesting a test through to receiving the result.

The tests are initially available on a private-pay basis, at A$495 for Promarker D and A$997 for Promarker Eso. Commercialisation remains at an early stage. Our focus is to help clinicians understand when to use the tests and translate that engagement into appropriate referrals, test volumes and revenue.

The collection pathways and operational experience established with Healius will also support the introduction of Promarker Endo.

Strategic Roadmap Immediate Focus

Our three-year roadmap begins with five immediate priorities for the remainder of FY2027.

First, build Australian adoption of Promarker D and Promarker Eso with Healius. We will measure progress through clinician engagement, appropriate referrals, test volumes and revenue.

Second, introduce Promarker Endo. We expect commercial availability between January and March 2027, subject to clinical deployment and applicable quality, accreditation and regulatory requirements. We will then focus on clinician engagement and adoption in Australian.

Third, advance reimbursement in Australia and the United States. We will progress health economic studies and clinical evidence, prepare applications and submit them when the supporting evidence is ready and the requirements are met. Approval, coverage and assessment timing remain subject to the relevant government bodies.

Fourth, establish US distribution. We are targeting an initial distributor appointment by end of June 2027. Once appointed, we will agree an implementation plan and phase recruitment and spending in line with that plan and available funding.

Fifth, deliver dependable testing and maintain capital discipline. We will monitor turnaround times, reporting quality and laboratory efficiency, while managing expenditure against budget and aligning investment with available funding.

Beyond FY2027, our focus in FY2028 is to broaden distribution, increase test use and publish evidence supporting adoption and reimbursement. In FY2029, we intend to improve distributor performance and operating efficiency, and develop opportunities for further product and geographic expansion.

We will report our progress against these priorities. For shareholders, the key measure is how effectively we turn access to our tests into sustained use and revenue growth.

Our Team

I would like to thank our people for the work that has brought us to this point. Their scientific expertise, commitment to quality and commercial focus, have supported validation, laboratory improvements and the Australian launch. I also thank the Board for its guidance and support through this transition.

Thank You

I am confident in the opportunity ahead. Our priorities are clear, and we will earn your continued confidence through disciplined execution and the progress we report.

Thank you for your continued support. I would now like to invite you all for refreshments.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

David Morris
CEO and Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Jane Lowe
Investor Relations
IR Department
T: +61 411 117 774
E:jane.lowe@irdepartment.com.au

Proteomics International
Laboratories Ltd

Annual General Meeting

Disciplined Path to Commercial Success

20 November 2026

ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia

Disclaimer

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

Execution Plan – Achievements to Date

We have built a strong foundation for commercial success.

RESET – FY26 H2

- ✓ Discontinued the DTC business model
- ✓ Engaged with potential distribution partners in Australia and the USA
- ✓ Continued Promarker Endo assay validation
- ✓ Refined Promarker Eso assay and streamlined lab protocols
- ✓ Restructured the leadership team and organisation
- ✓ Commenced the OxiDX strategic review
- ✓ Completed IP portfolio review

ACCESS – FY27 H1

- ✓ Appointed Healius as our Australian distribution partner
- ✓ Launched Promarker D and Promarker Eso in Australia and set test prices
- ✓ Refined and Validated Promarker Endo
- ✓ Developed reimbursement strategy for Australia and the USA
- ✓ Advanced laboratory processes, quality systems, and information systems in Australia

Product Innovation – Promarker Portfolio

Our portfolio of three prognostic and diagnostic tests target specific clinical areas of unmet need. Our priority is to commercialise these tests before developing new tests for other medical conditions.

Promarker D



Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, **enabling earlier clinical intervention and ongoing monitoring.**

Promarker Eso



Diagnostic blood test for patients with chronic reflux to rule out oesophageal adenocarcinoma, thus **reducing the need for invasive surveillance endoscopy procedures.**

Promarker Endo



Diagnostic blood test for patients with symptoms suggestive of endometriosis, **reducing the extensive delays in diagnosis and clinical management.**

Distribution – Healius Partnership

We have appointed Healius as our national distribution partner in Australia. Healius provides market access through its collection network and referrer relationships, and Proteomics delivers testing and clinical reporting.

Strategic Rationale

- National reach through existing pathology infrastructure.
- Access established GP and specialist referrers.
- Avoid building a proprietary collection network.
- Integrate tests into routine clinical workflows.

Proteomics

- Performs testing in accredited laboratories.
- Provides clinical reporting and scientific support.
- Maintains quality and regulatory compliance.
- Leads product development and clinical evidence.

healius pathology

- Exclusive Australian pathology distributor.
- Provides access to 1,900 collection centres.
- Collects specimens and distributes pathology services.
- Supports referrer engagement and market access.

Commercial Rollout

- ✓ Commenced Promarker D and Promarker Eso Australian national rollout on 26 October 2026
- ✓ Initial private pay patient prices: Promarker D A$495 and Promarker Eso A$997.
- ✓ Promarker Endo commercially available during FY27 Q3, pricing to be confirmed.

Strategic Roadmap – Immediate Focus

Our strategic roadmap outlines our 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value.

ADVANCE – FY27 H2

- **Drive adoption of Promarker D and Promarker Eso in Australia**
- **Launch Promarker Endo in Australia**
- **Advance reimbursement in Australia and USA**
- **Appoint distributor partner in the USA**
- **Optimise test turnaround times**
- **Complete OxiDx strategic review**
- **Maintain capital discipline**

ACCELERATE – FY28

- Broaden distributor network
- Increase awareness and test utilisation
- Manage reimbursement submissions and engagement processes
- Publish clinical utility and health economic evidence to support adoption and reimbursement
- Expand laboratory capacity and support functions in line with demand

ACHIEVE – FY29

- Enhance distributor performance management
- Expand product portfolio pipeline
- Streamline laboratory and commercial operations
- Improve operating leverage
- Develop strategic growth options to drive product and geographic expansion

Our Team

A capable and committed team, driven to deliver innovation and commercial success.















Proteomics International
Laboratories Ltd

Thank You

ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia